ClinicalTrials.gg
Drug

Cabergoline clinical trials

Also written Dostinex, Cabaser and FCE 21336.

studies test it
52
open now
11
in phase 3
16
first study started
2001

How each study uses Cabergoline is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Cabergoline studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Dec 1996 · DOSTINEX · NDA 020664 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cabergoline
36
Cabergoline 0.5 MG
6
Cabergoline 1 MG
3
Cabergoline (Dopamine Agonist)
2

Brand

Dostinex
19
Cabaser
2

Development codes

FCE 21336
2

Studies by the year they started

52 studies that test it; most in 2014 (6)

Studies that test Cabergoline, by start year
YearStudies
20013
20022
20031
20041
20052
20061
20071
20081
20091
20102
20111
20122
20131
20146
20152
20161
20172
20182
20192
20212
20222
20231
20242
20255
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
5
Phase 2
19
Phase 3
16
Phase 4
8
No phase
10

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 7 · Other 45

Stanford University (3) · Benha University (3) · Northwestern University (2) · Boston Children's Hospital (2) · Par Pharmaceutical, Inc. (2) · University of Sao Paulo General Hospital (2) · Novartis Pharmaceuticals (2) · Pfizer (2)

Often tested with

Tested in the same studies.

Metformin (2) · Pasireotide (2) · Levodopa (2) · Pyridoxine (1) · Calcium Gluconate (1) · Octreotide (1) · Pegvisomant (1) · Calcium Dobesilate (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 3 in phase 3

Studies that test Cabergoline, phase 3 first.

Studies

Open first, then newest update. How each study uses Cabergoline is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 52

See all 52 studies that test Cabergoline →

Given beside what is tested · 3 — Cabergoline is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with Cabergoline

Codes

What other systems call Cabergoline · ClinicalTrials.gg INT006730

  • MeSH (NLM) D000077465CabergolineConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) LL60K9J05TCABERGOLINEConfirmed FDA, NLM, Wikidata
  • RxNorm 47579Confirmed FDA, Wikidata
  • Wikidata Q423308cabergolineConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C47428CabergolineOne source FDA
  • DrugBank DB00248One source Wikidata

Also registered as cabergoline diphosphate (UNII 477M7SA9N9).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.